Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05313802 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3502970 in Healthy Overweight and Obese Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT05313802 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 72 participants.
The verdict
NCT05313802, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3502970 in healthy overweight and obese participants. The blood tests will be conducted to measure how much LY3502970 is in the bloodstream and how the body handles and eliminates LY3502970 in these participants. The study will last up to 42 days excluding the screening period.
Interventions
- DRUG LY3502970
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2022-05-26 |
| Est. Completion | 2022-09-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05313802
The ClinicalTrials.gov registry entry for NCT05313802 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LY3502970 is the first listed.
NCT05313802 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05313802 about?
NCT05313802 is a clinical study titled "A Study of LY3502970 in Healthy Overweight and Obese Participants". The main purpose of this study is to evaluate the safety and tolerability of LY3502970 in healthy overweight and obese participants. The blood tests will be conducted to measure how much LY3502970 is in the bloodstream and how the body handles and eliminates LY3502970 in these participants. The stud...
What is the current status of trial NCT05313802?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2022-05-26. Estimated completion is 2022-09-09.
What interventions are being tested in trial NCT05313802?
The interventions under investigation include: LY3502970 (DRUG).
Who is sponsoring clinical trial NCT05313802?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.